Search

Home > Research Groups > Dr Majdi Osman
Research Groups

Dr Majdi Osman

• Bio Sketch

Dr. Osman is Chief Medical Officer of OpenBiome, a non-profit spun out of the Massachusetts Institute of Technology (MIT) where he leads clinical and research programs developing new therapies targeting the gut microbiome. He is Co-PI on the first faecal microbiota transplantation (FMT) trial in Africa at the University of Cape Town. His research focuses on improving child health through understanding of the microbiome, reducing health disparities, and building capacity for translational research in Africa

 

• Research Interests

o Child health
o Microbiome
o Enteric infections
o Nutrition
o Health disparities

 

• Publications

• Allegretti JR, Elliott RJ, Ladha A, et al. Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation. Gut Microbes 2020; 1–3.

• Olesen SW, Zaman A, Osman M, Ramakrishna B. Modelling donor screening strategies to reduce the risk of SARS-CoV-2 via fecal microbiota transplantation. bioRxiv 2020.

• Olesen SW, Panchal P, Chen J, Budree S, Osman M. Global disparities in faecal microbiota transplantation research. Lancet Gastroenterol Hepatol 2020; 5: 241.

• Zellmer C, Budree S, Osman M, Panchal P. Diarrheal enteric pathogens associated with pediatric linear growth faltering: a systematic review of the literature. In: American Journal of Tropical Medicine and Hygiene. Amer Soc Trop Med & Hygiene 8000 Westpark Dr, Ste 130, Mclean, VA 22101 USA, 2019: 338.

• Osman M, Chen J, Dredge D. Incidentally Identified Duplication on Xp21. 1 Encoding the Dystrophin Gene in a 5 Year Old Boy with Normal Creatine Kinase (CK). In: ANNALS OF NEUROLOGY. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2019: S116–S116.

• Osman M. Hospitals attacked in Khartoum, Sudan. 2019.

• Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm EJ. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One 2019; 14.

• Kassam Z, Dubois NE, Ling K, et al. 512 – Donor Health Screening for Fecal Microbiota Transplantation: Prospective Evaluation of 15,317 Candidate Donors. Gastroenterology 2019; 156: S-100-S-101.

• Panchal P, Chen J, Pettee W, et al. Su1951 – Global Disparities and New Indications in Fecal Microbiota Transplantation Research: A Survey and Systematic Review of Clinical Trials Around the World. Gastroenterology 2019; 156: S-670-S-671.

• Santiago M, Eysenbach L, Allegretti J, et al. Microbiome predictors of dysbiosis and vre decolonization in patients with recurrent c. Difficile infections in a multi-center retrospective study. AIMS Microbiol 2019; 5: 1–18.

• Bajaj JS, Salzman NH, Acharya C, et al. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology 2019. DOI:10.1002/hep.30690.

• Bajaj JS, Salzman N, Acharya C, et al. PS-087-Fecal microbiota capsules are safe and effective in patients with recurrent hepatic encephalopathy: A randomized, blinded, placebo-controlled trial. J Hepatol 2019; 70: e55.

• Bajaj JS, Salzman N, Acharya C, et al. 245–Fecal Microbiota Capsular Transplant is Safe and Effective in Patients with Recurrent Hepatic Encephalopathy: A Randomized, Blinded, Placebo-Controlled Trial. Gastroenterology 2019; 156: S-1186.

• Osman M. A Clarification about Fecal Microbiota Transplantation. Sci. Am. https//blogs.scientificamerican.com/observations/a-clarification-about-fecal-microbiota-transplantation/. 2019.

• Kassam Z, Dubois N, Ramakrishna B, et al. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med 2019; : NEJMc1913670.

• Duvallet C, Zellmer C, Panchal P, Budree S, Osman M. Increasing fecal microbiota transplant clinical trialsuccessesby applying rational donor selection. Signat redacted 2019; : 112.

• Osman M, Zellmer C, Goddard E, et al. Transfer of healthy gut flora for restoration of intestinal microbiota via enema (THRIVE) for the rehabilitative phase of severe acute malnutrition: methodology for a novel pilot study evaluating safety, microbial engraftment and nutritional outcomes. Am J Trop Med Hyg 2018; 99: 592.

• Ling K, Ramakrishna B, Stoltzner Z, Kassam Z, Osman M, Panchal P. Stool Donor Demographics and Performance Indicators: Evidence From 223 Enrolled Stool Donors: 2878. Am J Gastroenterol 2018; 113: S1590.

• Panchal P, Kahn S, Zellmer C, et al. 533. Scaling Pediatric Access to Fecal Microbiota Transplantation in the United States: A Time-Series Geospatial Analysis. In: Open Forum Infectious Diseases. Oxford University Press US, 2018: S197–S197.

• Budree S, Osman M, Panchal P, et al. 618. Do Clinical Factors Affect Microbial Engraftment After Fecal Microbiota Transplantation in Recurrent Clostridium difficile Infection? In: Open Forum Infectious Diseases. Oxford University Press US, 2018: S225–6.

• Panchal P, Budree S, Scheeler A, et al. Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep 2018; 20. DOI:10.1007/s11894-018-0619-8.

• Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest. Endosc. 2018; 87: 18–29.

• Budree S, Osman M, Nduru P, et al. Evaluating the gut microbiome in children with stunting: findings from a south african birth cohort. In: american journal of tropical medicine and hygiene. Amer Soc Trop Med & Hygiene 8000 Westpark Dr, Ste 130, Mclean, VA 22101 USA, 2018: 198–9.

• Panchal P, Elliott RJ, Budree S, et al. 1010-Scaling Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficle Infection in the United States: A Geospatial Time-Series Analysis from 2013 to 2017. Gastroenterology 2018; 154: S-190.

• Osman M, Abend A, Panchal P, Kassam Z, Budree S. 88-Does the Donor Matter? Microbiome Sequencing to Evaluate Lower Donor Efficacy in Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection. Gastroenterology 2018; 154: S-25.

• Wong WF, Budree S, Osman M, et al. Tu1882-Fecal Microbiota Transplantation Improves Gastrointestinal Graft-Versus-Host Disease and Restores the Microbiome: A Pediatric Experience. Gastroenterology 2018; 154: S-1046.

• Panchal P, Budree S, Scheeler A, et al. Correction to: Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep 2018; 20: 28.

• Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1151–210.

• Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1260–344.

• Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–59.

• Panchal P, Budree S, Tu E, et al. Pediatric Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in the United States and the Impact of Stool Banks: A Geospatial Analysis. Gastroenterology 2017; 152: S849–50.

• Budree S, Rao S, Allegretti JR, et al. The Association of Donor Stool Consistency by Bristol Stool Scale on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection. Gastroenterology 2017; 152: S630.

• Budree S, Tu E, Leith T, et al. The Association of Stool Donor Diet on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection. Gastroenterology 2017; 152: S630–1.

• Budree S, Elliott RJ, Rao S, et al. Donor Stool Processing Time: The Effect on the Intestinal Microbiome and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection. Gastroenterology 2017; 152: S1006.

• Budree S, Wong WF, Tu E, et al. Do specific bacteria drive clinical cure in fecal microbiota transplantation for Clostridium difficile infection?: clinical, microbial and metabolomic characterization of universal FMT donors. Gastroenterology 2017; 152: S349.

• Razik R, Osman M, Lieberman A, Allegretti JR, Kassam Z. Faecal microbiota transplantation for Clostridium difficile infection: a multicentre study of non‐responders. Med J Aust 2017; 207: 159–60.

• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.

• GBD 2015 Mortality and Causes of Death Collaborators H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England) 2016; 388: 1459–544.

• Kassam Z, Lieberman A, Muñoz R, et al. the Impact of Stool Banks on Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in the United States: A Geospatial Analysis: 2016 Acg Presidential Poster Award: 948. Am J Gastroenterol 2016; 111: S410–1.

• Osman M, Stoltzner Z, O’Brien K, et al. Donor efficacy in fecal microbiota transplantation for recurrent Clostridium difficile: evidence from a 1,999-Patient Cohort. In: Open Forum Infectious Diseases. Oxford University Press, 2016.

• Eysenbach L, Allegretti JR, Aroniadis O, et al. Clearance of Vancomycin-Resistant Enterococcus Colonization With Fecal Microbiota Transplantation Among Patients With Recurrent Clostridium difficile Infection. Open Forum Infect Dis 2016; 3. DOI:10.1093/ofid/ofw172.1667.

• O’Brien K, Osman M, Eysenbach L, et al. Su1737 Clinical Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection From an International Public Stool Bank: Results From a 1,406 Patient Multi-Center Cohort. Gastroenterology 2016; 150: S539–40.

• Razik R, Osman M, Lieberman A, et al. Characterizing Patients Who Fail Fecal Microbiota Transplantation forClostridium difficileInfection: Results from a 135-Patient, Multi-center, Non-responder Cohort: 137. Am J Gastroenterol 2016; 111: S66.

• O’brien K, Petimar J, Ling K, et al. nutritional Composition of Stool Donors’ Diets Relative to That of the Us Population: Results from 44 Donors from an International Stool Bank for Fecal Microbiota transplantation: 1027. Am J Gastroenterol 2016; 111: S447–8.

• Nguyen LBL, Osman M, Chiang AL, et al. Su1745 the cost-effectiveness of competing strategies for treating severe-complicated Clostridium difficile infection: comparing fecal microbiota transplantation with standard colectomy. Gastroenterology 2016; 150: S543.

• Osman M, Khoiri A, Stoltzner Z, et al. clinical Effectiveness and Safety of Fecal Microbiota Transplantation in Children for Clostridium Difficile infection: Results from 9 Pediatric Centers in the United States: 2016 Acg Presidential Poster Award: 1038. Am J Gastroenterol 2016; 111: S452.

• Osman M, Dubois N, Gangireddy V, Amaratunga K, Allegretti JR, Kassam Z. the Great Mimic: Food-borne Illness Masquerading as an Infectious Adverse Event Following Fecal Microbiota Transplantation: 1326. Am J Gastroenterol 2016; 111: S592.

• Ling K, Koelsch E, Dubois N, et al. Prospective Laboratory Evaluation of Fecal Microbiota Transplantation Donors: Results From an International Public Stool Bank. Open Forum Infect Dis 2016; 3: 2123.

• Osman M, O’Brien K, Stoltzner Z, et al. Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection From An International Public Stool Bank: Results From a 2050-Patient Multicenter Cohort. Open Forum Infect Dis 2016; 3. DOI:10.1093/ofid/ofw172.1668.

• Kassam Z, Blackler D, Osman M, et al. Novel Safety Features in Fecal Microbiota Transplantation for RecurrentClostridium difficileInfection: Quality Assurance and Adverse Events Workflow: 1361. Am J Gastroenterol 2015; 110: S589.

• Dubois N, Ling K, Osman M, et al. Prospective assessment of donor eligibility for fecal microbiota transplantation at a public stool bank: results from the evaluation of 1387 candidate donors. In: Open Forum Infectious Diseases. Oxford University Press, 2015.

• Kassam Z, Fridman S, Burgess J, et al. the Cost-effectiveness of Competing Strategies for Managing Multiply Recurrent Clostridium difficile Infection: Examining the Impact of Universal Stool Banks and Encapsulated Fecal Microbiota Transplantation: 2247. Am J Gastroenterol 2015; 110: S933–4.

• Osman M, Daniels T. Survival at low lung function in cystic fibrosis: Cohort study from 1995 to 2010. 2012.

• Denno DM, Chandra-Mouli V, Osman M, et al. Reaching youth with out-of-facility HIV and reproductive health services: a systematic review. J Adolesc Health 2012; 51: 106–21.

• Kamara A, Dubrey S, Osman M, Mikel J, Phillips G. A puzzling tumour. Thorax 2012; 67: 1116–8.